Abstract Purpose: Ectopic expression of squamous cell carcinoma^related oncogene (SCCRO or DCUN1D1) in NIH-3T3 cells induces invasion in vitro and produces highly invasive xenografts in nude mice with a propensity for regional lymphatical metastasis. The aim of this study was to identify the molecular mechanism underlying SCCRO-induced invasion and metastasis. Experimental Design: The molecular mechanism of SCCRO-mediated effects on matrix metalloproteinase-2 (MMP2) levels and activity were assessed using a combination of cell biological and molecular methods, including real-time PCR, reporter assay, RNA interference, and chromatin immunoprecipitation assay. Tumor specimens from primary upper aerodigestive tract carcinomas (n = 89) were examined for levels of SCCRO, MMP2, MMP9, MT1-MMP, TIMP1, andTIMP2 mRNA by real-time PCR. Results: Overexpression of SCCRO increases MMP2 levels and activity, which is required for SCCRO-induced invasion. Modified McKay assays reveal that SCCRO does not bind to the MMP2 promoter, suggesting that its transcriptional effects are indirect. Deletion or mutation of the activator protein-2 (AP2) and p53 binding element within the MMP2 promoter abrogates SCCRO-driven activation. Ectopic expression of SCCRO increases AP2 levels and promotes the binding of p53 to the MMP2 promoter. Consistent with these findings, SCCRO and MMP2 are coexpressed (P < 0.0001; r 2 = 0.58; 95% confidence interval, 0.46-0.69) in primary (upper aerodigestive tract) carcinomas (n = 89), and this coexpression is associated with an increased prevalence of regional nodal metastasis (P = 0.04; relative risk, 1.53). Conclusions: SCCRO-induced invasion involves activation of MMP2 transcription in an AP2-and p53-dependent manner. SCCRO is a potential marker for metastatic progression in affected cancers.
Cancer cell invasion and metastasis is a complex, multistep process involving interactions between invading cells, the extracellular matrix, and other stromal elements (1) . Proteolytic enzymes secreted by tumor and/or host cells are required for cancer cells to invade the extracellular matrix and infiltrate lymphatic or blood vessel walls to metastasize to regional or distant sites. In addition, extracellular matrix proteolysis is also required for neoangiogenesis (2) . Several studies suggest that matrix metalloproteinases (MMP), a family of zinc-dependent endopeptidases, play a significant role in extracellular matrix invasion (3) . Two members of the MMP family, MMP2 (gelatinase A, 72-kDa type IV collagenase) and MMP9 (gelatinase B, 92-kDa type IV collagenase), are primarily responsible for invasion of the extracellular matrix and basement membrane. The expression of these gelatinases is relatively low in normal tissues and is induced when extracellular matrix remodeling is required. While gelatinase expression is primarily controlled at the transcriptional level, its activity is also regulated by posttranslational factors, including proenzyme activation by membrane-type MMPs and inhibition of enzyme activity by naturally occurring tissue inhibitor of metalloproteinase (TIMP). The aberrant expression or activation of MMP2 and MMP9 has been reported in many different human tumors and has been linked to enhanced tumor invasion or metastasis in in vitro and in vivo model systems (4 -12) . Supporting this association, oncogenetransformed human bronchial epithelial cells show an infiltrating capacity that correlates with a high expression of MMP2 mRNA (6, 7) . Moreover, MMP2-deficient mice show reduced angiogenesis and tumor progression, providing functional evidence of a role for MMP2 in tumor pathogenesis (13) .
Head and neck and lung squamous cell carcinomas commonly overexpress MMP2, with the level of expression correlated with increasing neoangiogenesis, invasion, and regional and distant metastases (5 -7, 11, 14 -17) . However, the mechanism of MMP2 activation in squamous cell carcinoma remains ill defined. We previously identified a novel oncogene [squamous cell carcinoma -related oncogene (SCCRO or DCUN1D1)] that is activated by amplification at the 3q26.3 locus. As part of this work, we found that SCCROtransformed NIH-3T3 cells have a significantly higher invasive capacity in vitro and in vivo (18) . Here, we show that the ectopic expression of SCCRO in NIH-3T3 cells results in the upregulation of MMP2, which is required for the SCCRO-driven invasion of extracellular matrices. SCCRO induces MMP2 transcription indirectly through the up-regulation of AP2 in a process requiring p53. Furthermore, the analysis of human cancers supports these findings and suggests that SCCRO is a putative marker for invasion and metastasis in squamous cell carcinoma.
Materials and Methods
Expression vectors and transfection. The open reading frame for SCCRO was cloned into mammalian expression vectors (pUSEamp or pTRE) by standard PCR cloning methods (Upstate Biotechnology). Transfections were performed using LipofectAMINE PLUS reagent (Life Technologies) and stable colonies selected for geneticin resistance. SCCRO -overexpressing NIH-3T3 clones were generated using pUS Eamp-SCCRO as previously described (18) . Scrambled specific RNAi against SCCRO were developed and optimized as described previously (18) .
Cell culture. Growth conditions for human cancer cell lines have previously been described (18, 19) . The murine embryonic fibroblastderived cell line (10.1) Val5 carrying the temperature-sensitive p53 allele and mouse embryonal fibroblasts with p53-homozygous deletion (p53 -/-) were obtained from Dr. Arnold Levine (Rockefeller University, New York, NY) and maintained as described (20) . EB1 cell line, a human colon carcinoma cell line stably transfected with a wild-type p53 gene under the transcriptional control of metallothionein MT1 promoter, was induced by adding 100 Amol/L zinc (21) .
Tissue samples. Fresh tissue samples were obtained from patients undergoing major surgical resection for head and neck or lung carcinomas following institutional guidelines after obtaining informed consent. Of the 89 primary head and neck or lung carcinomas, 77 were squamous cell carcinomas and 12 were adenocarcinomas. There were 44 males and 45 females with a median age at presentation of 65 y (range, 38-84 y). All patients were previously untreated. Following the institutional protocols based, on the site and stage of disease, adjuvant treatment was given following radical surgery in appropriate cases. In each case, the portion of tumor resected was near the advancing edge avoiding the necrotic center. After excision, the tissues were immediately snap frozen and stored in liquid nitrogen until use. Tumors were staged according to the American Joint Committee on Cancer tumornode-metastasis classification, 5th edition. Thirty-six cases were in pathologic stage I, 15 were in stage II, 20 were in stage III, and 18 were in stage IV.
Quantitative reverse transcription-PCR. For reverse transcription-PCR, total RNA was prepared from monolayers or homogenized snapfrozen tissue using TRIzol reagent (Life Technologies), following the manufacturer's protocol, and repurified with the RNeasy Mini spin column (Qiagen). RNA quantity and quality were evaluated by UV spectrophotometry and denaturing formaldehyde agarose gel electrophoresis. For reverse transcription, 2 Ag of total RNA were used for each reaction (Applied Biosystem). PCRs were performed using SYBR Green detection system on an I-cycler (Bio-Rad). 18S rRNA was used as a standard. Primer sets were designed using Primer3:
4 SCCRO, forward: ACTCGATCCAGCCAGCATTA and reverse: TGTTTGGAGAACTCG-CACTG; MMP1, forward: AGCTAGCTCAGGATGACATTGATG and reverse: CCGATGGGCTGGACAGG; MMP2 , forward: AGGGCA-CATCCTCTGACAGC and reverse: CGGTCGTAGTCCTCAGTGGT; MMP2, forward: CTTCGCTCGTTTCCTTCAAC and reverse: ATGTCA-GACAACCCGAGTCC; MMP9 , forward: AAGCTGGACTCGG-TCTTTGA and reverse: CCTGTGTACACCCACACCTG; MMP9, forward: CCACCGAGCTATCCACTCAT and reverse: CTGTCCCTAACGCCCAG-TAG; MT1-MMP, forward: GAGCTCAGGGCAGTGGATAG and reverse: TGAATGACCCTCTGGGAGAC; MT1-MMP, forward: GTTCGCCGAC-TAAGCAGAAG and reverse: AGGGAATTGCTCCTGGAAAT; TIMP1, forward: CATGGAAAGCCTCTGTGGAT and reverse: AAGAAGCTG-CAGGCATTGAT; TIMP2, forward: AGTTCTTCGCCTGCATCAAG and reverse: GTCGAGAAACTCCTGCTTGG; TIMP2, forward: CACAGACTT-CAGCGAATGGA and reverse: CCAGCATGAGACCTCACAGA.
In vitro migration and invasion assay. Migratory and invasive capacity were assessed by a modified Boyden chamber method as described previously (22) . Each assay was performed in triplicate. Invading cells were quantified by counting on a hemacytometer following trypsinization.
Quantitative zymography. Conditioned media were analyzed under nonreducing conditions and separated on 11% SDS-polyacrylamide gels copolymerized with 0.1% (w/v) gelatin to show gelatinolytic activity (MMP2 and MMP9) as described previously (22) . Duplicate gels were incubated as controls in buffer containing 5 mmol/L 1,10-phenanthroline to inhibit MMP activity. MMP activity was detected as clear zones of lysis against a blue background. The gel was dried with a gel drier and scanned thrice using an Arcus scanner, and the intensity of the bands (pixel unit) was quantified. Results were expressed in arbitrary 4 http://www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi
Translational Relevance
Combined, squamous cell carcinomas of the head and neck and lung account for a significant proportion of all human cancers. Although treatment approaches have evolved over the last few decades, the overall 5-year survival remains poor, primarily related to high rates of invasion and metastasis. Matrix metalloproteinases (MMP), especially MMP2, are commonly overexpressed in squamous cell carcinoma and are known to promote invasion through degradation of collagen in the basement membrane. Previously, we reported that the amplification and overexpression of squamous cell carcinoma^related oncogene (SCCRO) correlates with poor clinical outcome in squamous cell carcinoma. SCCRO-transformed NIH-3T3 cells have a significantly higher invasive capacity in vitro and in vivo. Here, we show that ectopic expression in NIH-3T3 cells and amplification-associated overexpression of SCCRO in human cancers correlate with increased MMP2 levels. We found that SCCRO induces MMP2 transcription indirectly through the up-regulation of activator protein 2 (AP2) in a process requiring p53. The clinical implications of our findings are twofold. First, our findings suggest that SCCRO may be a marker for invasion and metastasis in squamous cell carcinoma. In addition, definition of the mechanism by which SCCRO induces the overexpression of MMP2 provides an opportunity for therapeutic targeting.
units per 10 4 cells. Pilot studies using serial dilutions of standard MMP2/MMP9 (Chemicon International) showed a good linear correlation between the amount of MMP and the measured intensity in the range of 312.5 pg to 250 ng.
Transient transfection and reporter assay. Cells were seeded at a density of 1 Â 10 5 per well in six-well dishes and grown to 50% to 60% confluence at 37jC in DMEM containing 10% FCS, unless stated otherwise. Each well of cells was transfected with 1 Ag of plasmid DNA using the LipofectAMINE PLUS reagent. After 24 h, (10.1)Val5 cells were shifted to 32jC or 39jC and EB1 cells were treated with 100 Amol/L ZnCl 2 . Cells were harvested and lysed 48 h posttransfection, and luciferase activity was measured using a Dual-Light System (Applied Biosystems) in a TR717 microplate luminometer (Applied Biosystems). For each transfection, 100 ng of pSV-h-galactosidase were included to normalize for differences in transfection efficiency. Each experiment was done in triplicate and repeated thrice. Unless stated otherwise, transient transfections with the MMP2-luciferase construct used the fulllength promoter (1,659 bp). MMP2 promoter constructs were kindly provided by Dr. E.N. Benveniste (University of Alabama at Birmingham, Birmingham, AL).
Western blot analysis. Whole cell lysate or nuclear fractions were prepared following the manufacturer's protocols (Pierce Biotechnology). A rabbit polyclonal antibody against SCCRO protein was raised and affinity purified as described earlier (18) . Antibodies against p53, MMP2, AP2, and h-actin were from commercial sources (Sigma). Western blots were performed following standard protocols.
Modified McKay assay. Radiolabeled DNA of a 1,659-bp MMP2 promoter region was incubated with lysates made from HeLa cells transfected with a hemagglutinin (HA)-SCCRO construct. SCCRO-DNA complexes were immunoprecipitated with an anti-HA antibody and detected by autoradiography.
Chromatin immunoprecipitation. Chromatin immunoprecipitation was done with a commercially available kit (Upstate Cell Signaling Solutions) according to the manufacturer's protocols. Purified fragmented DNA was used for PCR with two sets of primers spanning sequential and overlapping segments of the MMP2 promoter. The sequence of primers used were primer set A, forward CCTGAACTT-GTCTGAAGCCC and reverse TCTGAGCTGAGACCTGAAGA, and primer set B forward ACACCCACCAGACAAGCCTG and reverse CCTGACTTCAGCCCCTAAAC.
Statistical analysis. All statistical analyses were done using the JMP software system version 4.0. Results were expressed as mean F SE. For comparison of the levels of mRNA expression between groups, the twotailed Mann-Whitney (rank sum) test and the Kruskal-Wallis test with Dunn's multiple comparison test were used comparing two and three groups, respectively. The contingency table with Fisher's exact test was used to assess the association between SCCRO mRNA expression and clinicopathologic parameters. Correlations between the mRNA levels were computed using the two-tailed Spearman nonparametric correlation. All P values were two-sided. P <0.05 was considered statistically significant.
Results
SCCRO overexpression induces invasion by the activation of MMP2. Our earlier observations showed that the overexpression of SCCRO in NIH-3T3 cells produces invasion in vitro and highly invasive nude mouse xenografts that develop regional lymph node metastasis (18) . To determine the role of SCCRO in invasion, we stably transfected NIH-3T3 cells and selected two clones (3T3/SCCRO14 and 3T3/SCCRO28) expressing SCCRO at levels similar to that seen in cancer cell lines with high levels of 3q amplification (18) . An empty vectortransfected clone (3T3/Vector) was also established for use as a control. To assess migratory ability, we subjected 3T3/ SCCRO14, 3T3/SCCRO28, and 3T3/Vector cells to a modified Boyden chamber assay without reconstituted basement membrane. The vector-and SCCRO-transfected cells showed similar migratory ability (Fig. 1A) . Next, we assessed invasive capability Fig. 1 . Effects of SCCRO on MMP2 activity. A, SCCRO-transfected NIH-3T3 (3T3/SCCRO14 and 3T3/SCCRO28) and vector control (3T3/Vector) cells were seeded onto a reconstituted basement membrane or onto an uncoated filter to determine the invasion or migration, respectively. The number of invading cells was measured after 6 h of incubation and expressed as percentage invasion (black columns), and the migration of the indicated clones after 6 h was compared by measuring the number of cells migrating through the uncoated filters (instead of Matrigel-coated filters). Both clones showed migratory ability similar to the vector control. *, P < 0.05. B, gelatin zymography of MMP2 activity. Conditioned media collected from both the SCCRO-transfected clones were concentrated, and protein concentration was quantitated. Equal amounts of protein were run for carrying out SDS-PAGE gelatin zymography. Gelatin lysis bands appear as clear areas against the blue background. Latent and active forms of MMP2 are shown. C, invasion assay on 3T3/SCCRO28 cells in the presence of varying concentrations of MMP2 inhibitor. TIMP2 shows a dose-dependent inhibition of invasion. *, P < 0.05. by quantifying the ability of cells to traverse Matrigel-coated filters in the modified Boyden chamber assay relative to the number of cells passing through the uncoated filters. The Matrigel matrix forms a physical barrier resembling the extracellular matrix that must be degraded for cells to cross into the lower chamber in the modified Boyden chamber invasion assay. 3T3/SCCRO 14 and 3T3/SCCRO 28 cells possessed significantly higher invasive capability compared with the 3T3/Vector cells that rarely succeeded in traversing the Matrigel barrier (P < 0.001; Fig. 1A ). The increase in the invasive capacity of cells transfected with SCCRO suggests that they have enhanced proteolytic activity leading to the degradation of the Matrigel. Several studies have shown that gelatinase (MMP2 and MMP9) plays an essential role in the degradation of the extracellular matrix. We examined the changes in the levels and activity of MMP2 and MMP9 (gelatinases A and B) in the conditioned media from SCCRO-transfected cells by gelatin zymography and densitometry. Three gelatinolytic bands were detected in the serum-free medium, 72, 62, and 59 kDa, representing latent, intermediate, and active forms of MMP2, respectively. Vector-transfected 3T3 cells secreted lower levels of MMP2 in all the three forms. In contrast, 3T3/SCCRO14 and 3T3/SCCRO28 cells showed high levels of secretion and proteolytic activation of all three forms of MMP2 (Fig. 1B) . To confirm the requirement of MMP2 for increased invasion in SCCRO-transformed cells, we performed invasion assays in the presence and absence of physiologic MMP inhibitors (TIMPs), including TIMP2 (preferentially inhibits MMP2) and TIMP1 (inhibits MMP9 as well as other MMPs; ref. 23) , showing a dose-dependent decrease in invasion by SCCRO-transfected NIH-3T3 cells with TIMP2 (IC 50 value of 229.5 nmol/L; Fig. 1C ), but not TIMP1. Similar results were seen with the addition of anti-MMP2 antibody to the media, but not anti-MMP9 (data not shown). These findings suggest that the increased invasive capacity resulting from ectopic SCCRO expression requires MMP2 activity.
SCCRO up-regulates MMP2 transcription. As a step toward understanding the mechanism of increased invasion in SCCRO-transformed cells, we quantitated the mRNA levels of MMP2, MMP9, MT1-MMP (proenzyme responsible for the Tet-off-SCCRO).Tetracycline was removed from the growth media at the indicated time points, and the levels of SCCRO and MMP2 were determined byWestern blot analyses. C, mRNA levels of MMP2 relative to SCCRO as determined by real-time PCR, expressed as fold change in a tetracycline-regulated SCCRO expression system as in B. RNA extracted from cells at the indicated time points following tetracycline withdrawal from growth media. *, P < 0.05. D, transfection of SCCRO-RNAi into head and neck cancer cell lines with (MDA886) and without (584) SCCRO amplification results in a specific knockdown of SCCRO and a corresponding decrease in MMP2 levels only in cell lines carrying SCCRO amplification.
activation of gelatinases), TIMP1, and TIMP2 in our NIH-3T3 lines by real-time reverse transcription-PCR. Whereas no changes were seen for MMP9, MT1-MMP, TIMP1, and TIMP2 expression (data not shown), the levels of MMP2 mRNA were significantly higher in 3T3/SCCRO14 and 3T3/SCCRO28 relative to control 3T3/Vector cells ( Fig. 2A) . To validate this association, we developed a regulated SCCRO expression system (SCCRO-Tet-off) wherein the levels of SCCRO increased with the removal of tetracycline from the medium. The open reading frame of SCCRO was cloned into a pTRE vector and stably transfected into murine embryonic fibroblasts/3T3 cells expressing tetracycline-controlled transactivator and assessed for changes in MMP2 and MMP9 expression in relation to SCCRO levels. The removal of tetracycline from the media resulted in an increase in SCCRO and a concomitant increase in MMP2 levels, as determined by Western blot and real-time PCR analyses (Fig. 2B and C) . No change in SCCRO or MMP2 expression was seen in the presence of tetracycline in the media (data not shown). Next, we assessed the effects of SCCRO knockdown using RNAi on MMP2 expression. We had previously developed and optimized an RNAi system for the specific targeting of SCCRO and confirmed that it effectively reduced SCCRO protein levels. Specific knockdown in cell lines with SCCRO amplification (MDA886) but not those without it (584) resulted in decreased MMP2 expression (Fig. 2D) .
To determine if the positive correlation between SCCRO and MMP2 levels is due to MMP2 being a transcriptional target of SCCRO, we performed a reporter assay using a construct containing a luciferase gene driven by a 1,659-bp fragment of human MMP2 promoter. Transfection of the MMP2 reporter construct into 3T3/SCCRO28 resulted in a significant increase in luciferase activity compared with the control 3T3/Vector ( Fig. 3A; 1,639 bp) . These results suggest that MMP2 is a transcriptional target of SCCRO. To determine if SCCRO activates MMP2 transcription by directly interacting with MMP2 promoter, we performed a modified McKay assay using the 1,659-bp human MMP2 promoter fragment to assess for the binding interaction between SCCRO and the MMP2 promoter. This analysis showed that SCCRO does not bind to the MMP2 promoter, suggesting that the effect of SCCRO on the MMP2 promoter is indirect, apparently requiring other factors (data not shown).
SCCRO cooperates with AP2 or p53 for the transactivation of the MMP2 promoter. Unlike MMP9, only a few transcription factors have been shown to directly regulate MMP2 transcription, including p53, Sp1, Sp3, and AP2 (24 -27) . In addition, analysis of the MMP2 promoter reveals several putative cisacting regulatory elements, including p53, activator protein-1, Ets-1, CAAT/enhancer binding protein, cyclic AMP -responsive element binding protein, polyoma enhancer activator 3, Sp1, and AP2, which could also be involved in the regulation of MMP2 transcription. To identify the location of the SCCROinducible regulatory element in the MMP2 promoter, NIH-3T3/ SCCRO14, NIH-3T3/SCCRO28, and NIH-3T3/Vector cells were transfected with reporter constructs containing serial deletions of the MMP2 promoter. Activation observed with the full-length construct (1,659-bp promoter region) was lost with the deletions of the first 30 bp from the 5 ¶ end of the MMP2 promoter (Fig. 3A) . Analysis of the promoter region containing the putative SCCRO-responsive element identified consensus binding sites for p53 and AP2, both of which have previously been shown to be functionally active (28) . To determine if they are involved in SCCRO-mediated activation of the MMP2 promoter, point mutations in the p53 and AP2 binding sites of the MMP2-promoter reporter construct, were generated by PCR mutagenesis (p53-1, p53-2, AP2, p53-1/2, Cotransfection of SCCRO or empty vector with wild-type or mutated MMP2 promoter construct into NIH-3T3 cells showed that the mutation of either p53 or AP2 binding sites alone decreased the promoter activity, whereas double mutation in the p53 and AP2 binding sites resulted in the complete abrogation of SCCRO-associated MMP2 promoter activity (Fig. 3B) . These results suggest that the SCCRO-dependent activation of the MMP2 promoter is cooperatively mediated through the p53 and AP2 sites. This is consistent with recent reports from Mertens and colleagues (29) showing that p53-AP2 protein complexes bind to and activate the MMP2 promoter.
SCCRO increases AP2, but not p53, protein expression. To determine if SCCRO up-regulates AP2 and/or p53, we assessed the levels of AP2 and p53 in 3T3/SCCRO14, 3T3/SCCRO28, and 3T3/Vector cells by Western blot. AP2 protein levels were higher in SCCRO-transfected cells relative to vector-transfected control, whereas no change was observed in the levels of p53 showing MMP2 activity in the aforementioned transfected cell lysates. E, chromatin immunoprecipitation assay on cells transfected with a regulated SCCRO-expressing plasmid (SCCRO-Tet-off). Six hours after tetracycline was withdrawn from growth media, p53 was immunoprecipitated, and the immunoprecipitate was subjected to PCR using primers spanning the MMP2 promoter. (Fig. 3C) . This suggests that the activation of MMP2 promoter may be related to increased AP2 protein levels in SCCROtransfected cells.
Wild-type p53 is required for the SCCRO-induced activation of MMP2 transcription. To begin to determine the role of p53 in SCCRO-induced MMP2 transcriptional activation, p53 -/-murine embryonic fibroblasts and p53-mutated (H520 and H1299) or wild-type (584) cancer cell lines were cotransfected with SCCRO (pUSEamp/SCCRO) and the MMP2 reporter construct. Transient SCCRO expression had no effect on MMP2 promoter activity in p53 -/-murine embryonic fibroblasts or cancer cell lines with p53 mutation, whereas it increased MMP2 promoter activity in murine embryonic fibroblasts and cancer cell lines (584) with wild-type p53 (data not shown). To confirm the requirement for p53, we repeated these experiments in murine embryonic fibroblast -derived Val5 cell line (10.1) containing a temperature-sensitive p53 mutant that is wild type at 32jC and mutant at 39jC (30) . MMP2 promoter activity increased in Val5 cells at a temperature (32jC) wherein it expresses wild-type p53, but not at 39jC wherein it expresses a mutant form of p53 (Fig. 4A) . Quantitative zymography on conditioned media from these cells showed an increase in MMP2 activity in SCCRO-transfected Val5 cells at 32jC (wild-type p53), but not at 39jC (mutant p53; Fig. 4B ). To corroborate these findings, we repeated these experiments in EB1 colon carcinoma cells containing zinc-inducible p53 expression. The p53 expression was not detectable in EB1 cells in the absence of zinc but was induced by zinc exposure as confirmed by Western blot analysis (data not shown). MMP2 transcription and activity were significantly higher in SCCROtransfected EB1 cells when zinc was added to the media relative to zinc-free conditions (Fig. 4C and D) . These data suggest that wild-type p53 is required for SCCRO-induced transcriptional activation of MMP2.
SCCRO increases the binding of p53 to the MMP2 promoter. To determine if an increase in SCCRO levels results in increased p53 binding to the MMP2 promoter in vivo, we conducted a chromatin immunoprecipitation assay. Anti-p53 antibody was used to immunoprecipitate p53-containing complex from extracts of NIH-3T3 cells expressing SCCRO under the control of a tetracycline repressible promoter. Primers spanning the MMP2 promoter were used for PCR. PCR of the immunoprecipitates of cells grown in the presence of tetracycline (basal level of SCCRO) or subsequent to its removal (elevated SCCRO levels) showed an increase in the yield of PCR product in the latter, suggesting that an increase in SCCRO levels increases the binding of p53 to the MMP2 promoter (Fig. 4E) . The levels of p53 was not affected by tetracycline (data not shown). Taken together, these observations strongly suggest that p53 is involved in the SCCRO-associated activation of MMP2 transcription. Because published data suggest that the p53-AP2 protein complex binds to and activates the MMP2 promoter, the observed findings of increase in the binding of p53 to the MMP2 promoter with the expression of SCCRO likely represents p53 in complex with AP2. The expression of SCCRO correlates with MMP2 expression and regional nodal metastases in mucosal squamous cell carcinoma. We next aimed to determine whether the associations identified in our experimental cell lines exist in human tumors. Tumor specimens from primary upper aerodigestive tract carcinomas (head and neck regions, 54; lung, 35; total, 89) were examined by real-time PCR for levels of SCCRO, MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA, along with matched and histologically normal adjacent tissue for each case. In addition, SCCRO expression correlated with the presence of nodal metastasis at presentation in patients with head and neck squamous cell carcinoma (Table 1 ; P = <0.001; relative risk, 2.58; 95% CI, 1.49-4.44) and patients with lung squamous cell carcinoma (Table 2 ; P = 0.001; relative risk, 2.52; 95% CI, 1.29-4.89). Subset analysis of cases overexpressing SCCRO showed a stronger association with nodal metastasis when MMP2 was coexpressed (relative risk, 3.08; 95% CI, 1.63-5.84; P < 0.01). There was no correlation between nodal metastasis and other clinicopathologic parameters, including age, gender, smoking, alcohol, T classification, and histologic grading (Tables 1 and 2 ). These findings suggest that SCCRO may be responsible for MMP2 expression in human cancers carrying 3q amplification and that SCCROassociated overexpression of MMP2 is a marker for metastatic progression in affected cancers.
Discussion
Malignant transformation is often associated with the transcriptional activation of MMP2. A number of oncogenes such as p60v-src, yes, fps, and crk have been associated with the augmented secretion and activation of MMP2 (31) . The oncogene-induced activation of MMP2 transcription has been shown to involves a number of potential cis-acting regulatory elements, including p53, Ets-1, CAAT/enhancer binding protein, cyclic AMP -responsive element binding protein, polyoma enhancer activator 3, Sp1, and AP2 (24 -26, 32 -34) . In this study, we found that SCCRO-induced invasion involves the transcriptional up-regulation of MMP2. Similar to what has been shown for other oncogenes, the mechanism by which SCCRO induces MMP2 expression is indirect. SCCRO increases AP2 protein levels, which in turn bind to the MMP2 promoter in conjunction with p53 to activate MMP2 transcription. Although p53 protein levels are not affected, binding of p53 to the MMP2 promoter is enhanced by SCCRO expression. The deletion or mutation of the p53 and/or AP2 binding sites in the MMP2 promoter abrogates SCCRO-induced activation. Similarly, the SCCRO-induced activation of MMP2 transcription is lost in p53-deficient systems, including murine embryonic fibroblasts from p53 knockout mice.
The involvement of p53, a well-established tumor suppressor gene, in promoting pro-oncogenic MMP2 activity may seem paradoxical but is supported by several previous studies. MMP2 is up-regulated when p53 is activated in cell lines consequent to etoposide (28) , g-irradiation (25, 35, 36) , and ischemia (37) . Moreover, several other metastasis-associated genes are (35, 36) . Interestingly, p53 transcriptional activity in these settings typically requires cooperation with other transcription factors. Previous studies have shown that the tandem array of AP2 and p53 regulatory elements in the upstream region of MMP2 and other genes activate transcription (38 -40) . The AP2/p53 binding region in MMP2 (-1,657/-1,619 bp) is highly conserved, further supporting its functional importance (41) . Furthermore, we have shown that 3q amplification and p53 mutations rarely occur in the same tumor, suggesting that there may be divergent pathways for the activation of MMP2 in squamous cell carcinoma (42) .
Because SCCRO is overexpressed in 30% to 50% whereas MMP2 is activated in the majority of cases, other mechanisms of MMP2 activation are also active in squamous cell carcinoma. Our findings suggest that the SCCRO-induced activation of MMP2 transcription exploits AP2/p53 interaction. Although it is clear that the affinity of p53 for the MMP2 promoter increased with an increase in the levels of SCCRO, the precise mechanisms involved remain to be defined. The simplest explanation is that the increased AP2 levels in SCCROoverexpressing cells results in the efficient recruitment of the p53-AP2 complex to the MMP2 promoter. Although our findings show the effector component of the mechanism by which SCCRO activates invasion, the specific method for the activation of MMP2 in this process remains to be defined. Analysis of DCN1 and DCN1p, the Caenorhabditis elegans and Saccharomyces cerevisiae orthologues of SCCRO, suggest that SCCRO is involved in neddylation and, in turn, ubiquitinbased protein degradation (43, 44) . We have observed similar findings with the murine and human orthologues, suggesting that posttranscriptional regulation may play a role in SCCROinduced invasion (45) .
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